Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome analysis of hepatocellular carcinoma and adjacent non-tumor liver tissues [II]

ABSTRACT: Transcriptome analysis of hepatocellular carcinoma and adjacent non-tumor liver tissues [II]

PROVIDER: PRJNA976244 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24738842.fastq.gz	Fastqsanger.gz
	SRR24738842_1.fastq.gz	Fastqsanger.gz
	SRR24738842_2.fastq.gz	Fastqsanger.gz
	SRR24738843.fastq.gz	Fastqsanger.gz
	SRR24738843_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

Transcriptome analysis of hepatocellular carcinoma and adjacent non-tumor liver tissues [II]

Project description:To study its expression and regulatory functions in hepatocellular carcinoma (HCC) progression, whole transcriptome RNA sequencing in paired HCC tumor and adjacent non-tumor liver tissue samples from 3 local Hispanic patients was performed.

2024-09-25 | GSE233421 | GEO

Transcriptome analysis of hepatocellular carcinoma and adjacent non-tumor liver tissues [I]

Project description:Integrin alpha 6 (ITGA6) forms integrin receptors with either integrin β1 (ITGB1) or integrin beta 4 (ITGB4). To study its expression and regulatory functions in hepatocellular carcinoma (HCC) progression, whole transcriptome RNA sequencing in paired HCC tumor and adjacent non-tumor liver tissue samples from ten local Hispanic patients was performed. The average expression of ITGA6 was found increased by over 3.5-fold in HCC tumor tissues in comparison with their adjacent non-tumor tissues. The study indicates integrin alpha6-beta4 complex as a potential therapeutic target for treating patients in HCC.

2022-05-18 | GSE202853 | GEO

RNA-Seq expression profiling of hepatocellular carcinoma and adjacent non-tumor liver tissues

Project description:Three pairs of hepatocellular carcinoma and adjacent non-tumor tissues were from 3 male patients suffering from stage I or II HCC with hepatitis C virus background. RNA-Seq libraries were prepared from total RNA using polyA enrichment strategy. The libraries were sequenced on Illumina HiSeq2000 instruments.

2016-11-18 | GSE81550 | GEO

Transcriptome analysis between hepatocellular carcinoma and adjacent tissues

Project description:Transcriptome analysis between hepatocellular carcinoma and adjacent tissues

| PRJNA894511 | ENA

Transcriptome analysis between hepatocellular carcinoma and adjacent tissues

Project description:mRNA/ lncRNA/ circRNA profiles of hepatocellular carcinoma and the adjacent tissues were generated by deep sequencing using Illumina NovaSeq 6000.

2022-10-31 | GSE216613 | GEO

Transcriptome analysis of hepatocellular carcinoma and adjacent non-tumor liver tissues [I]

Project description:Transcriptome analysis of hepatocellular carcinoma and adjacent non-tumor liver tissues [I]

| PRJNA837535 | ENA

Gene expression profiling of 18 hepatocellular carcinoma and adjacent non-tumorous liver tissue

Project description:These paired HCC and non-tumorous liver tissues were used to determine highly differentially expressed genes in HCC and non-tumorous liver tissue. Hepatocellular carcinoma (HCC) is a malignancy with poor survival outcome. Genes showing extreme differential expression between paired human HCC and adjacent non-tumorous liver tissue were investigated. PLVAP was identified as a gene specifically expressed in vascular endothelial cells of HCC but not in non-tumorous liver tissues. This finding was confirmed by RT-PCR analysis of micro-dissected cells and immunohistochemical staining of tissue sections. A recombinant monoclonal anti-PLVAP Fab fragment co-expressing extracellular domain of human tissue factor (TF) was developed. The potential therapeutic effect and toxicity to treat HCC were studied using a Hep3B HCC xenograft model in SCID mice. Infusion of recombinant monoclonal anti-PLVAP Fab-TF into the tumor feeding artery induced tumor vascular thrombosis and extensive tumor necrosis at doses between 2.5 µg and 12 µg. Tumor growth was suppressed for 40 days after a single treatment. Systemic administration did not induce tumor necrosis. Little systemic toxicity was noted for this therapeutic agent. The results of this study suggest that anti-PLVAP Fab-TF may be used to treat HCC cases for which transcatheter arterial chemoembolization (TACE) is currently used, but without major drawbacks of TACE. Anti-PLVAP Fab-TF may improve therapeutic outcome and be a viable therapeutic agent in patients with more advanced disease and compromised liver function. Frozen hepatocellular carcinoma and adjacent non-tumorous liver tissues were used for gnee expression profiling study. Affymetrix U133A genechips were used for gene expression profiling. This dataset is part of the TransQST collection.

2015-01-01 | E-GEOD-60502 | biostudies-arrayexpress

DNA-Seq of human hepatocellular carcinoma and adjacent tissues to determine differetiatial expression of microRNA

Project description:Determine differetiatial expression of micro RNA in paired human hepatocellular tumor tissues and their adjacent cirrosis tissues by SOLiD sequencing. http://www.appliedbiosystems.com/absite/us/en/home/applications-technologies/solid-next-generation-sequencing/small-rna-analysis.html Matrix with results is available in thearchive: E-MTAB-511.additional.zip

2011-10-01 | E-MTAB-511 | biostudies-arrayexpress

Microarray expression data for tumor and adjacent non-tumor tissues from hepatocellular carcinoma patients

Project description:Here we aimed to develop a new molecular prognostic stratification system for hepatocellular carcinoma (HCC) patients after liver resection based on common prognostic factors for primary tumors (PTs) and adjacent non-tumor tissues (ANTTs). We studied global mRNA expression profiles from 115 PT tissue samples and 52 ANTT samples derived from 115 HCC patients. Methods for the study included gene expression analysis, Functional Annotation/Gene Ontology analysis and unsupervised survival prognosis approach based on Cox hazards prognosis model. This study provides a practical prognostic system for reliable identification of the high-risk HCC patients subgroup with clearly described deregulated molecular machinery in both PTs and ANTTs.

2017-05-26 | GSE76427 | GEO

cDNA microarray of hepatocellular carcinoma and nontumor liver tissues

Project description:In order to identify the deregulated genes in hepatocellular carcinama, we applied the Agilent two-color chip cDNA microarray to explore the expression of genes in hepatocellular carcinoma and nontumor liver tissue samples. Hepatocellular carcinoma tissues and nontumor liver tissues were obtained from hepatocellular carcinoma patients during surgery. In these samples, RNA was extracted and cDNA microarray was performed to identify the differentially expressed genes in these samples. Hepatocellular carcinoma tissues and nontumor liver tissues were obtained from hepatocellular carcinoma patients during surgery. We included four hepatocellular carcinoma patients in this study, and there are four nontumor tissues and four hepatocellular carcinoma tissues.

2011-12-23 | E-GEOD-34674 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data